8-K filing — Allarity Therapeutics, Inc. (ALLR)
Filed: 2026-08-14 AccNo: 0001213900-26-090183 Size: 303 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Allarity Therapeutics Receives U.S. Patent And Trademark Office Patent For Its Drug Response Predictor Companion Diagnostic
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jun 30, 2026, 12:04 PM
- Checked
- Jun 30, 2026, 12:10 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Allarity Therapeutics Q2 EPS $(0.21) Beats $(0.25) Estimate
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.25) by 16 percent. This is a 40 percent decrease over losses of $(0.15) per share from
Read original at benzingaAllarity Therapeutics Secures CLIA For In-House Lab
Read original at benzinga